Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Other EventsItem 8.01 Other Events.
On April 13, 2017, Lee Allen, M.D., Chief Medical Officer of Argos Therapeutics (the “Company”), voluntarily resigned from the Company effective as of that date. There were no disagreements between Dr. Allen and the Company or any officer or director of the Company which led to Dr. Allen’s resignation. Dr. Allen had served as Chief Medical Officer since January 2016.
About Argos Therapeutics, Inc. (NASDAQ:ARGS)
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial. Argos Therapeutics, Inc. (NASDAQ:ARGS) Recent Trading Information
Argos Therapeutics, Inc. (NASDAQ:ARGS) closed its last trading session up +0.028 at 0.390 with 688,401 shares trading hands.